The MHRA have published details of the suspension of licences for gadodiamide (Omniscan) and intravenous gadopentetic acid (also known as gadopentetate dimegulumine; Magnevist), taking effect from 1 February 2018. Further restrictions have been applied to other linear Gadolinium-containing contrast agents.
This update is in response to a European-level scientific review of gadolinium retention in the brain and other tissues. Currently, there is no evidence of harm due to gadolinium retention in the brain, although the data are limited.
Full details can be found here, which also links to the MHRA’s Central Alerting System message to healthcare professionals.
